SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO) as of late introduced that it intends to supply and promote, in an underwritten public providing and matter to marketplace and different stipulations, $175 million of stocks of its not unusual inventory. The entire stocks are being presented via Allogene. As well as, Allogene intends to grant the underwriters for the providing a 30-day possibility to buy as much as an extra $26.25 million of the stocks of its not unusual inventory presented within the public providing. There can also be no assurance as as to if or when the providing could also be finished, or as to the real dimension or phrases of the providing.
Allogene expects to make use of the web proceeds from this providing for common company functions, which would possibly come with scientific trial bills, analysis and construction bills, common and administrative bills, and capital expenditures.
Goldman Sachs & Co. LLC, Jefferies and TD Cowen are appearing because the joint book-running managers for the providing. TPG Capital BD, LLC is appearing as co-manager for the providing.
This press liberate shall now not represent an be offering to promote or the solicitation of an be offering to shop for those securities, nor shall there be any sale of those securities in any state or different jurisdiction wherein such be offering, solicitation or sale can be illegal previous to the registration or qualification underneath the securities regulations of such a state or different jurisdiction.
About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology corporate pioneering the improvement of allogeneic chimeric antigen receptor T cellular (AlloCAR T) merchandise for most cancers and autoimmune illness. Led via cellular treatment veterans making use of confirmed CAR T revel in, Allogene is growing a pipeline of off-the-shelf CAR T cellular product applicants with the function of handing over readily to be had cellular treatment on-demand, extra reliably, and at better scale to extra sufferers.
Cautionary Notice on Ahead-Taking a look Statements Positive statements on this press liberate are forward-looking statements that contain plenty of dangers and uncertainties. Those statements could also be recognized via introductory phrases corresponding to “may,” “expects,” “goal,” “intend,” “will,” “would,” “subject to” or phrases of identical that means, or via the truth that they don’t relate strictly to historic or present info. Such forward-looking statements come with statements relating to Allogene’s expectancies with admire to the final touch, timing and dimension of the proposed public providing, the usage of proceeds from the providing and granting the underwriters a 30-day possibility to buy further stocks. For such statements, Allogene claims the safety of the Non-public Securities Litigation Reform Act of 1995. Precise occasions or effects would possibly range materially from Allogene’s expectancies. Components that would purpose precise effects to range materially from the forward-looking statements come with, however don’t seem to be restricted to, dangers and uncertainties related to marketplace stipulations and the pride of commonplace last stipulations associated with the proposed providing, and the ones elements disclosed in Allogene’s filings with the SEC, together with its Annual Record on Shape 10-Okay for the 12 months ended December 31, 2025, filed with the SEC on March 12, 2026, and different filings that Allogene would possibly make every so often with the SEC. Those forward-looking statements constitute Allogene’s judgment as of the time of this liberate. Allogene disclaims any intent or legal responsibility to replace those forward-looking statements, instead of as could also be required underneath appropriate legislation.
